Consequently, NSAIDs are potentially able to favor cancer prophylaxis and regression by inhibiting COX-2/PGE2, which may partly explain why NSAIDs may improve survival in patients receiving ICIs to a certain extent compared to opioids. The gene discussed is PTGS2; the disease is cancer.